TRANXENE

This brand name is authorized in United States. It is also authorized in France, Lithuania, Netherlands, Poland, Tunisia.

Active ingredients

The drug TRANXENE contains one active pharmaceutical ingredient (API):

1	Clorazepate UNII 63FN7G03XY - CLORAZEPATE DIPOTASSIUM
	Clorazepate is a benzodiazepine with anxiolytic, sedative, hypnotic, and anticonvulsant properties. Clorazepate exerts its effect by de-activating the nervous system through potentiation of the inhibitory effect of gamma-aminobutyric acid (GABA) on the GABA-A receptors by binding to a site that is distinct from the GABA binding site.
	Read more about Clorazepate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRANXENE Tablet	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05BA05	Potassium clorazepate	N Nervous system → N05 Psycholeptics → N05B Anxiolytics → N05BA Benzodiazepine derivatives
Discover more medicines within N05BA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	62416105, 67956742, 68494908, 68644101
LT	Valstybinė vaistų kontrolės tarnyba	1001901, 1001902, 1093496, 1093497, 1093498, 1093499, 1093500, 1093501
NL	Z-Index G-Standaard, PRK	22020, 41807, 7684, 7692
PL	Rejestru Produktów Leczniczych	100067544, 100067550, 100067567, 100278212, 100291715, 100324981, 100335476, 100335750, 100335766, 100350620, 100354195, 100362600, 100363260, 100363343, 100365626, 100365840, 100369794, 100370774, 100380130, 100408732, 100409513, 100412320, 100414431, 100418015, 100460489
TN	Direction de la Pharmacie et du Médicament	6250212, 6250213
US	FDA, National Drug Code	55292-304